Status:

COMPLETED

Сohort Study to Evaluate Exacerbations, Respiratory Symptoms, Physical Exercise Intolerance and Lung Functions Among Participants Who Use IQOS With Heatsticks Compared to Smokers of Conventional Cigarettes

Lead Sponsor:

Kazakhstan Academy of Preventive Medicine

Collaborating Sponsors:

Philip Morris International

Synergy Research Group

Conditions:

Pulmonary Disease, Chronic Obstructive

Respiratory Insufficiency

Eligibility:

All Genders

40-59 years

Brief Summary

This study evaluates frequency of exacerbations, respiratory symptoms, physical exercise intolerance and abnormal lung functions among participants who use IQOS with heatsticks compared to smokers of ...

Detailed Description

Heated Tobacco Products, such as Heatsticks heated by iQOS device, are specially designed tobacco products that contain tobacco material and several filter sections. Recent studies demonstrate that th...

Eligibility Criteria

Inclusion

  • Male or female
  • Age 40-59 years inclusive
  • Smoking history ≥10 pack-years (for both cohorts)
  • Ability to follow study procedures

Exclusion

  • Pregnant women; Legally incapable individuals;
  • Patients with history of:
  • chronic infectious and non-infectious lung disease except asthma (e.g. pulmonary fibrosis, bronchiectasis, cystic fibrosis, tuberculosis, etc.) diagnosed prior to or during the first visit to KAPM COPD Center;
  • previous surgical excision of at least one lung lobe (or having undergone a lung volume reduction procedure);
  • active cancer of any localization under treatment;
  • suspected cancer of any localization;
  • metallic articles in the chest;
  • recent eye surgery (during the last 6 month prior to the visit);
  • episode (s) of myocardial infarction within less than 6 months prior to the visit or another form of acute or chronic coronary heart disease, history of heart rhythm abnormality with episode of arrhythmia within the last 6 months prior to the visit or long lasting that requires continuous drug therapy;
  • acute episode of cerebrovascular ischemic attack within the last 12 month prior to the visit;
  • chest or abdominal surgery performed within the last 6 month prior the visit;
  • contraindications to salbutamol or refusal to inhale salbutamol;
  • chest radiation therapy within the last 12 month prior to the visit; radiology diagnostic procedures of chest within the last 6 months prior to the visit;
  • recent (6 weeks before the visit) respiratory tract infection (colds, flus), fever of any etiology with increasing temperature over 37 C at the time of the visit and in the last 2 weeks prior to the visit;
  • significant history of alcohol abuse or consumption of more than recommended units of alcohol per week (28 units male and 21 units female);
  • positive screening test for HIV antibodies or positive screening for TB, if available at the time of first visit;
  • elevated blood pressure (systolic) is ≥160 mmHg at the moment of visit. PMI employees and first degree relatives

Key Trial Info

Start Date :

December 16 2017

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

November 30 2023

Estimated Enrollment :

1200 Patients enrolled

Trial Details

Trial ID

NCT03383601

Start Date

December 16 2017

End Date

November 30 2023

Last Update

December 15 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Kazakhstan Academy of Preventive Medicine

Almaty, Kazakhstan, 050008